Clinical Trial Update: A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating an HCV polymerase inhibitor pro-drug in combination with pegylated interferon alfa-2a (Pegasys) with or without ribavirin (Copegus) for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Copegus (ribavirin)
• HCV polymerase inhibitor pro-drug
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED